CLINICAL RESEARCH: HEART FAILURE
Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide in the General Community
Determinants and Detection of Left Ventricular Dysfunction
Lisa C. Costello-Boerrigter, MD, PhD*, ,*,
Guido Boerrigter, MD*,
Margaret M. Redfield, MD*,,
Richard J. Rodeheffer, MD,
Lynn H. Urban, MS ,
Douglas W. Mahoney, MS,
Steven J. Jacobsen, MD, PhD ,
Denise M. Heublein, CLT* and
John C. Burnett, Jr, MD*,
* Cardiorenal Research Laboratory, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota.
Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota.
Division of Biostatistics, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota.
Division of Epidemiology, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota.
Manuscript received April 27, 2005;
revised manuscript received August 26, 2005,
accepted September 8, 2005.
* Reprint requests and correspondence: Dr. Lisa C. Costello-Boerrigter, Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905. (Email: costello.lisa{at}mayo.edu).
OBJECTIVES: This study sought to characterize factors influencing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) and to evaluate the ability of NT-proBNP to detect left ventricular (LV) dysfunction in a large community sample.
BACKGROUND: Secretion of BNP increases in cardiac disease, making BNP an attractive biomarker. Amino-terminal proBNP, a fragment of the BNP prohormone, is a new biomarker. We evaluated factors influencing NT-proBNP in normal patients and compared the ability of NT-proBNP and BNP to detect LV dysfunction in a large community sample.
METHODS: Amino-terminal pro-BNP was determined in plasma samples of a previously reported and clinically and echocardiographically characterized random sample (n = 1,869, age  45 years) of Olmsted County, Minnesota.
RESULTS: In normal patients (n = 746), female gender and older age were the strongest independent predictors of higher NT-proBNP. Test characteristics for detecting an LV ejection fraction  40% or 50% were determined in the total sample with receiver operating characteristic curves. Amino-terminal pro-BNP had significantly higher areas under the curve for detecting an LV ejection fraction 40% or 50% than BNP in the total population and in several male and age subgroups, whereas areas were equivalent in female subgroups. Age- and gender-adjusted cutpoints improved test characteristics of NT-proBNP. Both assays detected patients with systolic and/or moderate to severe diastolic dysfunction to a similar degree, which was less robust than the detection of LV systolic dysfunction alone.
CONCLUSIONS: Amino-terminal pro-BNP in normal patients is affected primarily by gender and age, which should be considered when interpreting values. Importantly, in the entire population sample NT-proBNP performed at least equivalently to BNP in detecting LV dysfunction and was superior in some subgroups in detecting LV systolic dysfunction.
|
Abbreviations and Acronyms
| | AUC = area under the curve | | BMI = body mass index | | BNP = B-type natriuretic peptide/brain natriuretic peptide | | DD = diastolic dysfunction | | EF = ejection fraction | | GFR = glomerular filtration rate | | HF = heart failure | | HR = heart rate | | NT-proBNP = amino-terminal pro-B-type natriuretic peptide | | LA = left atrial | | LR = likelihood ratio | | LV = left ventricular | | LVSD = left ventricular systolic dysfunction | | ROC = receiver-operating characteristic |
|
This article has been cited by other articles:
|
|
|
|
 
K. M. Eggers, A. S. Jaffe, L. Lind, P. Venge, and B. Lindahl
Value of Cardiac Troponin I Cutoff Concentrations below the 99th Percentile for Clinical Decision-Making
Clin. Chem.,
January 1, 2009;
55(1):
85 - 92.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Tagore, L. H. Ling, H. Yang, H.-Y. Daw, Y.-H. Chan, and S. K. Sethi
Natriuretic Peptides in Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol.,
November 1, 2008;
3(6):
1644 - 1651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Eggers, L. Lind, H. Ahlstrom, T. Bjerner, C. Ebeling Barbier, A. Larsson, P. Venge, and B. Lindahl
Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects
Eur. Heart J.,
September 2, 2008;
29(18):
2252 - 2258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C H J Michielsen, J. A Bakker, R. R J V. Kimmenade, Y. M Pinto, and M. P V. Dieijen-Visser
The diagnostic value of serum and urinary NT-proBNP for heart failure
Ann Clin Biochem,
July 1, 2008;
45(4):
389 - 394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Perik, B. Rikhof, F. A. de Jong, J. Verweij, J. A. Gietema, and W. T. A. van der Graaf
Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity
Ann. Onc.,
February 1, 2008;
19(2):
359 - 361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Daniels and A. S. Maisel
Natriuretic Peptides
J. Am. Coll. Cardiol.,
December 18, 2007;
50(25):
2357 - 2368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mogelvang, J. P. Goetze, P. Schnohr, P. Lange, P. Sogaard, J. F. Rehfeld, and J. S. Jensen
Discriminating Between Cardiac and Pulmonary Dysfunction in the General Population With Dyspnea by Plasma Pro-B-Type Natriuretic Peptide
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1694 - 1701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Borlaug, V. Melenovsky, M. M. Redfield, K. Kessler, H.-J. Chang, T. P. Abraham, and D. A. Kass
Impact of Arterial Load and Loading Sequence on Left Ventricular Tissue Velocities in Humans
J. Am. Coll. Cardiol.,
October 16, 2007;
50(16):
1570 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
Circulation,
July 31, 2007;
116(5):
e99 - e109.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Omland, M. S. Sabatine, K. A. Jablonski, M. M. Rice, J. Hsia, R. Wergeland, S. Landaas, J. L. Rouleau, M. J. Domanski, C. Hall, et al.
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
205 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Emdin, C. Passino, C. Prontera, M. Fontana, R. Poletti, A. Gabutti, C. Mammini, A. Giannoni, L. Zyw, G. Zucchelli, et al.
Comparison of Brain Natriuretic Peptide (BNP) and Amino-Terminal ProBNP for Early Diagnosis of Heart Failure
Clin. Chem.,
July 1, 2007;
53(7):
1289 - 1297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Clerico, M. Fontana, L. Zyw, C. Passino, and M. Emdin
Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review
Clin. Chem.,
May 1, 2007;
53(5):
813 - 822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Heublein, B. K. Huntley, G. Boerrigter, A. Cataliotti, S. M. Sandberg, M. M. Redfield, and J. C. Burnett Jr
Immunoreactivity and Guanosine 3',5'-Cyclic Monophosphate Activating Actions of Various Molecular Forms of Human B-Type Natriuretic Peptide
Hypertension,
May 1, 2007;
49(5):
1114 - 1119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Ammar, S. J. Jacobsen, D. W. Mahoney, J. A. Kors, M. M. Redfield, J. C. Burnett Jr, and R. J. Rodeheffer
Prevalence and Prognostic Significance of Heart Failure Stages: Application of the American College of Cardiology/American Heart Association Heart Failure Staging Criteria in the Community
Circulation,
March 27, 2007;
115(12):
1563 - 1570.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S.P. Lam, J. C. Burnett Jr, L. Costello-Boerrigter, R. J. Rodeheffer, and M. M. Redfield
Alternate Circulating Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide Forms in the General Population
J. Am. Coll. Cardiol.,
March 20, 2007;
49(11):
1193 - 1202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. M. Corteville, K. Bibbins-Domingo, A. H. B. Wu, S. Ali, N. B. Schiller, and M. A. Whooley
N-Terminal Pro-B-Type Natriuretic Peptide as a Diagnostic Test for Ventricular Dysfunction in Patients With Coronary Disease: Data From the Heart and Soul Study
Arch Intern Med,
March 12, 2007;
167(5):
483 - 489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol.,
December 19, 2006;
48(12):
2575 - 2583.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Goetze, R. Mogelvang, L. Maage, H. Scharling, P. Schnohr, P. Sogaard, J. F. Rehfeld, and J. S. Jensen
Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction
Eur. Heart J.,
December 2, 2006;
27(24):
3004 - 3010.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Abroug, L. Ouanes-Besbes, N. Nciri, N. Sellami, F. Addad, K. B. Hamda, A. B. Amor, M. F. Najjar, and J. Knani
Association of Left-Heart Dysfunction with Severe Exacerbation of Chronic Obstructive Pulmonary Disease: Diagnostic Performance of Cardiac Biomarkers
Am. J. Respir. Crit. Care Med.,
November 1, 2006;
174(9):
990 - 996.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Belluardo, A. Cataliotti, L. Bonaiuto, E. Giuffre, E. Maugeri, P. Noto, G. Orlando, G. Raspa, B. Piazza, L. Babuin, et al.
Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy
Am J Physiol Heart Circ Physiol,
October 1, 2006;
291(4):
H1529 - H1535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Felker, J. W. Petersen, and D. B. Mark
Natriuretic peptides in the diagnosis and management of heart failure.
Can. Med. Assoc. J.,
September 12, 2006;
175(6):
611 - 617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Masson, R. Latini, I. S. Anand, T. Vago, L. Angelici, S. Barlera, E. D. Missov, A. Clerico, G. Tognoni, J. N. Cohn, et al.
Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data
Clin. Chem.,
August 1, 2006;
52(8):
1528 - 1538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. McKie, R. J. Rodeheffer, A. Cataliotti, F. L. Martin, L. H. Urban, D. W. Mahoney, S. J. Jacobsen, M. M. Redfield, and J. C. Burnett Jr
Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide: Biomarkers for Mortality in a Large Community-Based Cohort Free of Heart Failure
Hypertension,
May 1, 2006;
47(5):
874 - 880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
